Upload
navojit-chowdhury
View
227
Download
0
Embed Size (px)
Citation preview
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 1/23
Drug Presentation
Presenter:DR. MD. ARIFUR RAHMAN
MD (Cardiology), Final Part StudentNICVD, DHAKA.
Moderator:
DR. MOHAMMAD ULLAH FIROZAssistant professor, Dept.of CardiologyNICVD, DHAKA.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 2/23
Left AtrialAppendage
Occlusion Device
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 3/23
Background
Atrial fibrillation (AF) is the most common sustainedcardiac rhythm disturbance, increasing in prevalence withage.
Stroke is the most feared consequence of AF and mostthrombi associated with AF arise within the left atrialappendage.
AF confers an increased relative risk of overall mortality(average 1.7 times controls) and is predominantly causedby stroke.
Stroke prevention is the major focus of management ofpatients with AF.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 4/23
Background(cont.)
Anticoagulation is the treatment of choice to prevent
stroke in AF.
Anticoagulation has many side effects such as intracranialor gastrointestinal hemorrhage.
Closing the left atrial appendage (LAA) might be analternative in patients who cannot take anticoagulationtreatment due to contraindications, intolerance or
conditions in which the hazard of hemorrhage is greaterthan the potential clinical benefits.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 5/23
Left Atrial Appendage Occlusion Device Percutaneous occlusion of the LAA is a new approach
used to prevent strokes in high-risk patients with AF.
This device is a permanent implant that blocks theconnection between the left atrium and the LAA, thus
prevents embolism.
Currently, two devices have been developed:
1.The PLAATO system ( Appriva Medical Inc)
2.The WATCHMAN filter system (Atritech, Inc)
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 6/23
The PLAATO device
The PLAATO (Percutaneous Left Atrial AppendageTranscatheter Occlusion) device was the first successfulimplanted occluder in a human.
It was first introduced in August 2001.
The PLAATO framework consists of Nitinol in a basket-
type configuration with a tissueanchoring system on thestruts designed to maintain the correct position of thedevice.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 7/23
A nonthrombogenic PTFE membrane covers thebasket structure and is designed to seal the orificeof the LAA and allow tissue adhesion.
The device is available in seven sizes ranging from15 to 32 mm in diameter.
The PLAATO device is introduced via a 14-Fr gaugetransseptal sheath system.
The PLAATO device
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 8/23
The PLAATO device
A.PLAATO deviceB. Angiographic view of the PLAATO device after its release
into the left atrial appendage from the delivery catheterC. The device in situ as seen on a plain radiograph
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 9/23
Angiogram of the LAA: (a) after venous and transseptal puncture a specially
designed transseptal sheath is advanced into the LAA,dye injection provides information on the diameter ofthe ostium and the morphology of the LAA
b) proximal and (c) distal dye injection after device’s expansion reveal the degree of occlusion.
The PLAATO device
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 10/23
Transesophageal echocardiography shows the LAA
before(left) and after (right) the PLAATO procedure
The PLAATO device
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 11/23
The WATCHMAN filter system
The Watchman implant is the newest of the LAA
occluding systems and was very recently introduced
into clinical studies (2005).
It is a self-expanding nitinol frame structure coveredwith a permeable (160-micron pores) polyester fabricthat faces the left atrial side of the device.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 12/23
The WATCHMAN filter system
It has a row of fixation barbs to ensure the greaterstability of the device and is available in diametersranging from 21 to 33 mm.
The Watchman filter system consists of an integral
12-Fr delivery system preloaded with the device and a14-Fr transseptal access sheath. The filter is releaseddistal to the left atrial ostium.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 13/23
The WATCHMAN filter system
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 14/23
Introduction Sheath With Double and
Single Curve for Different Anatomical Situations
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 15/23
The WATCHMAN® device (Atritech,Inc., North Plymouth, MN)
Syed TM and Halperin JL (2007) Left atrial appendage closure for stroke
prevention in atrial fibrillation: state of the art and current challenges Nat Clin Pract Cardiovasc Med 4: 428–435 doi:10.1038/ncpcardio0933
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 16/23
The WATCHMAN filter system
Successful placement of the device is defined ifthe LAA is completely sealed with absence of flowor minimal flow (jet <3 mm) as measured by TEEat 45 days.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 17/23
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 18/23
Clinical TrialsPROTECT AF Trial: The WATCHMAN filter system
The effects of the Watchman device on the incidenceof stroke, TIA, systemic embolism, and cardiovasculardeath will be compared to conventional therapy withdose-adjusted warfarin in a multicenter prospective
randomized study in approximately 500 patients with AF.
If TEE performed at 45 days demonstratessatisfactory LAA occlusion, patients who received aWatchman device will discontinue therapy withwarfarin and will receive clopidogrel 75 mg for 6months followed by aspirin 325 mg for the duration ofthe trial (5 years). The study started in December2005.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 19/23
The PLAATO device:
Within two prospective, multi-center trials, LAAocclusion was attempted in 111 patients (age 71-91years) with PLAATO device since August 2001. Allpatients had a contraindication for anticoagulationtherapy and at least one additional risk factor forstroke.
Among 111 patients, the complication rate was 6% to
7%; the annual rate for stroke or transient ischemicattacks, 5.5%; and the annual mortality, 6.6%.
Clinical Trials
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 20/23
Indication
Age> 18 years with high risk of stroke.
Paroxysmal, persistent or permanent AF.
Contraindications to long term anticoagulationtherapy.
Intolerance to anticoagulation therapy.
Bleeding complications.
S
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 21/23
Summery
The most significant risk associated with atrial
fibrillation (AF) is arterial thromboembolism andstroke.
Conventional anticoagulant therapy is highlyeffective but is not consistently applied to allthose at risk because of the inconvenience ofregular INR monitoring and fears relating to
bleeding complications.
7/27/2019 Left Atrial Appendage Occlusion Device, nicvd
http://slidepdf.com/reader/full/left-atrial-appendage-occlusion-device-nicvd 22/23
A raft of new drugs and mechanically basedtherapies is now being actively investigated, and
results are promising so far.
It is very likely that the clinical approach to thethromboembolism risk management strategy inpatients with AF will change substantially in thevery near future with a bit of help from cardiacinterventions.
Summery(cont.)